Jassi

• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca … Recruiting
  2022-502352-31-00 5 2025-02-10 Colorectal Cancer (CRC)
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides difficile Infection: The Re … Recruiting
  2022-502972-22-00 5 2024-10-31 Clostridioides difficile infection.
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• A phase 3 trial of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia Recruiting
  2022-500583-36-00 5 2024-07-01 Acute Schizophrenia
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting
  2023-505251-43-00 5 2024-02-28 Primary Biliary Cholangitis
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU … Recruiting
  2023-507372-42-00 4 2021-09-20 Schizophrenia
• A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to … Recruiting
  2022-502519-13-00 5 2021-05-07 Moderate to Severe Plaque Psoriasis
• A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection Ended recruitment
  2025-521096-31-00 5 2025-10-02 Chronic Hepatitis C Virus (HCV) Infection
• A study to learn about the safety of long-term treatment with brivaracetam in children and young adults with childhood or juvenile absence e … Ended recruitment
  2023-508095-11-00 5 2024-11-27 Childhood Absence Epilepsy
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell … Ended recruitment
  2024-513539-25-00 4 2024-11-22 Type 2 Diabetes Mellitus
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended recruitment
  2022-502669-14-00 5 2023-12-18 Small cell lung cancer (SCLC)
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended recruitment
  2023-506867-33-01 4 2022-01-25 Chronic Hepatitis B

Showing 25–48 of 75 trials